Cerebrovascular DiseaseB-MRVCNCT07264972
Creation of a Biological Collection for Medical Research Purposes for Patients at the Reference Center for Rare Diseases of the Blood Vessels of the Brain and Eye at Lariboisière Hospital
An observational study of Cerebrovascular Disease, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
The aim of establishing a biological collection associated with the existing rare cerebral vascular disease cohort is to identify new prognostic or disease progression biomarkers that could improve patient care or identify new therapeutic targets. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cerebrovascular Disease
- What is being tested?
- additional samples for research purposes
- How many people
- 500 participants
- Where
- 1 siteFrance
- Study dates
- 21 Jan 2021to 31 Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with rare cerebrovascular diseases
Who may be able to join
- Confirmed diagnosis of a rare cerebral vascular disease of the brain, including:
- Familial intracranial aneurysms, cerebral amyloid angiopathy, CADASIL, familial cerebral cavernoma, familial cervical or intracranial artery dissection, vascular leukoencephalopathy (hereditary), familial hemiplegic migraine, cerebral arteriovenous malformation, moya-moya, cerebral venous thrombosis, hereditary retinal tortuosity, cerebro-retinal vasculopathies, other known rare diseases, or other rare diseases that are undetermined or not yet described.
- Participation in the MVCR cohort
- Adults >18 years old
- Affiliation with French social security or beneficiary - Signature of informed consent
Who cannot join
- Incompatibility with long-term follow-up at CERVCO
- Patient under guardianship/conservatorship
- Pregnant or breastfeeding women
- Patient under AME
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Constitution d'Une Collection Biologique à Des Fins de Recherche médicale Pour Les Patients du Centre de référence Des Maladies Rares Des Vaisseaux du Cerveau et de l'Oeil à l'hôpital Lariboisière
The aim of establishing a biological collection associated with the existing rare cerebral vascular disease cohort is to identify new prognostic or disease progression biomarkers that could improve patient care or identify new therapeutic targets.
- Conditions
- Cerebrovascular Disease
- Being tested
- additional samples for research purposes
- Keywords
- rare cerebrovascular disease
- Medical subject headings
- Cerebrovascular Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
additional samples for research purposesOther
Blood and urine sampling
| Study group | Role | What they receive |
|---|---|---|
| Patients with rare cerebrovascular disease | Not described Receives: Other: additional samples for research purposes |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time required for sample storage (freezing) to ensure the stability of most measurable elements in a biological sample
for each sample
Measured: Up to 2 years after inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2025
- Study start21 Jan 2021
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebrovascular DiseaseStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07264972
- Sponsor's protocol ID
- APHP200773
- Acronym
- B-MRVC
- Status last verified
- Nov 2025
- First submitted
- 24 Nov 2025
- Last updated
- 4 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Constitution d'Une Collection Biologique à Des Fins de Recherche médicale Pour Les Patients du Centre de référence Des Maladies Rares Des Vaisseaux du Cerveau et de l'Oeil à l'hôpital Lariboisière
- ClinicalTrials.gov ID
- NCT07264972
- Acronym / sponsor ID
- B-MRVC / APHP200773
- Conditions
- Cerebrovascular Disease
- Keywords
- rare cerebrovascular disease
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (actual)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 21 Jan 2021 (actual)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Jul 2027 (estimated)
- First posted
- 4 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of establishing a biological collection associated with the existing rare cerebral vascular disease cohort is to identify new prognostic or disease progression biomarkers that could improve patient care or identify new therapeutic targets.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with rare cerebrovascular disease | – | Other: additional samples for research purposes |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with rare cerebrovascular diseases
Key inclusion criteria (5 listed)
- Confirmed diagnosis of a rare cerebral vascular disease of the brain, including:
- Familial intracranial aneurysms, cerebral amyloid angiopathy, CADASIL, familial cerebral cavernoma, familial cervical or intracranial artery dissection, vascular leukoencephalopathy (hereditary), familial hemiplegic migraine, cerebral arteriovenous malformation, moya-moya, cerebral venous thrombosis, hereditary retinal tortuosity, cerebro-retinal vasculopathies, other known rare diseases, or other rare diseases that are undetermined or not yet described.
- Participation in the MVCR cohort
- Adults >18 years old
- Affiliation with French social security or beneficiary - Signature of informed consent
Key exclusion criteria (4 listed)
- Incompatibility with long-term follow-up at CERVCO
- Patient under guardianship/conservatorship
- Pregnant or breastfeeding women
- Patient under AME
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| additional samples for research purposesBlood and urine sampling | Other | Patients with rare cerebrovascular disease |
Primary outcome
Time required for sample storage (freezing) to ensure the stability of most measurable elements in a biological sample
Time frame: Up to 2 years after inclusion
for each sample
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Cerebrovascular Disease
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cerebrovascular Disease, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time required for sample storage (freezing) to ensure the stability of most measurable elements in a biological sample (time frame: Up to 2 years after inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.